key: cord-0714037-1ljoh343
authors: Trindade, Arvind J.; Zhang, Jianying; Hauschild, John; Leggett, Cadman L.; Iyer, Prasad G.
title: Impact of COVID-19 on the diagnosis and therapy for Barrett’s esophagus and esophageal cancer in the United States
date: 2021-11-19
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.11.020
sha: 111ea55a486b4809339534cbe399356bb88ed133
doc_id: 714037
cord_uid: 1ljoh343

nan

Barrett's esophagus (BE) is a precancerous condition in which normal squamous esophageal mucosa is replaced by specialized intestinal metaplasia 1 . It is the main risk factor for esophageal adenocarcinoma. Patient's that are high-risk for BE and that meet screening criteria are eligible for endoscopy 2 . If dysplastic BE is found then patients undergo ablation therapy which can decrease the progression to advanced neoplasia 3, 4 .

The coronavirus disease 2019 (COVID-19) has affected healthcare throughout the world. With healthcare efforts geared towards curtailing the virus, cancer screening programs resources have decreased 5 ; especially those involving elective procedures in the United States 6, 7 . It is unclear how the pandemic has affected the diagnosis and therapy of BE and esophageal cancer in the United States.

We conducted a retrospective study using the large claims database, Premier Table 1 shows the average number of monthly cases A) by yearly, quarterly, and B) monthly. Compared to the corresponding months in 2019, between April 2020 and June 2020 (second quarter), the average number of monthly cases for newly diagnosed BE and BE endoscopic ablation deceased by 68.3% (p=0.0009) and 51.8%(p=0.0685) respectively. Compared to the corresponding months in 2020, between January and March 2021 (first quarter), the average number of monthly cases for all cohorts had no significant difference (p>0.05).

The results indicate that early esophageal cancer is likely being undiagnosed or untreated during COVID-19. Meanwhile, those undergoing esophagectomy are more likely to be advanced cancers that are symptomatic. One would expect a rising trend for the diagnosis of BE and esophageal cancer for the first quarter of 2021 to compensate for the decrease. This is seen in our data; however, this trend is not statistically significant compared to 2020 data. In addition, the decrease in ablation of Barrett's is concerning as dysplastic lesions are high risk for progression to cancer. The expected consequence of our findings would be a sharp rise of diagnosis of esophageal cancer, which is likely too early to see in our study period.

To date there is one Irish study that examines the impact of COVID-19 on the diagnosis of esophageal cancer and BE 8 . A 26% decline in esophagogastric cancer and a 59% decrease in BE diagnosis was observed. This study only examined the pandemic period from March to September 2020 and did not examine ablation and esophagectomy trends.

Our study has several strengths. It uses a large database of BE patients that capture unique patients that can be tracked between visits. In addition, we only included patients in which the hospitals reported data for the entire study period. This allows for a more accurate estimation of the impact of COVID-19 on the endoscopic or surgical therapy utilization for diagnosis and therapy of BE and esophageal cancer.

Our study does have limitations. The billing codes cannot distinguish between esophageal adenocarcinoma and squamous cell cancer or the stage of cancer.

However, our aim was to examine all esophageal cancer in the United States. In addition, this dataset accuracy is dependent on accuracy of billing codes, as is the case for all large insurance claims databases.

In conclusion, we show from a large database, that the new diagnosis of BE and esophageal cancer has decreased during COVID-19 along with endoscopic ablation therapy; however, the number of esophagectomies has not been significantly 

Patients with newly diagnosed BE: We included all adult patients who were newly diagnosed with BE in each month during the study period. BE was identified by using International Statistical Classification of Diseases the 10th revision (ICD-10-CM) J o u r n a l P r e -p r o o f diagnosis codes of BE (Appendix 1). "Newly diagnosed BE" was defined as a) no BE diagnosis was found within 12 months prior to the new BE diagnosis; b) an esophagogastroduodenoscopy (EGD) was performed within seven days to three months prior to new BE diagnosis.

2) BE patients with endoscopic ablation: We included all adult patients who were diagnosed with BE and had an endoscopic ablation procedure during our study period.

The following patients were excluded from the cohort. a) who had a diagnosis of esophageal or stomach cancer 6 months prior to the index diagnosis; b) who had an esophageal ablation procedure within six months prior to index diagnosis. c) who had an endoscopic resection on the same day of endoscopic esophagus ablation. Endoscopic esophagus ablation and endoscopic resection were identified by using the Current Procedural Terminology (CPT®) codes (Appendix 1) Billing codes for radiofrequency ablation and cryotherapy are the same and thus cannot be differentiated within a dataset.

3) Patients with esophagectomy: We included all adult patients who had an esophagectomy procedure for esophageal cancer (including gastric cardia cancer).

Esophagectomy was identified by using International Statistical Classification of Diseases the 10th revision (ICD-10-PCS) surgical codes. Esophageal cancer was identified by using ICD-10-CM diagnosis codes of esophageal cancer (Appendix 1).

were newly diagnosed with esophageal cancer each month during the study period. The newly diagnosed esophageal cancer diagnosis was defined as 12 months prior to the new diagnosis, no esophageal or stomach cancer were found and EGD was performed within seven days to three months prior to the new diagnosis. Esophageal cancer was identified by using ICD-10-CM diagnosis codes of esophageal cancer (Appendix 1).

Data from Jan 2019 to Apr 2021 was used to identify the cases for each cohort. We used calendar year 2018 data to identify proceeding diagnosis or procedures to meet our Bivariate analysis was used to compare the difference in numbers of cases between different time periods. T-test was used for testing the statistical significance and it was two-tailed and was set at p < 0.05. Data preparation and analyses were performed using SAS software (version 9.4, SAS Institute, Inc., Cary NC, USA. 

B (Monthly)

Negative (-) indicates the volume increase.**CY: Calendar Year; Bolded number indicates P value<0.05. Newly Diagnosed BE BE Endoscopic Alation Newly Diagnosed Esophageal Cancer Esophagectomy Year

J o u r n a l P r e -p r o o f